Identifying markers for MPNST to improve diagnosis and surgery
Part of Brain & nervous system, Cancer clinical trials.
This trial collects tissue samples from people with MPNST or neurofibroma during surgery to find metabolic markers that could help diagnose MPNST faster and ensure complete removal of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with MPNST (a type of nerve tumor) or neurofibroma (a non-cancerous nerve growth).
- You are scheduled for surgery to remove the tumor as part of your usual care.
- You are at least 1 year old.
- Your tumor can be measured (at least 1 cm) on a scan or physical exam.
- You are able to understand and sign a consent form (or have a parent do so if you are under 18).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
This study is looking for adults with NF1 who have had a plexiform neurofibroma. It aims to find better ways to detect tumors early, which could help with treatment decisions.
This trial tests two targeted drugs, mirdametinib and vorinostat, to see if they can shrink MPNST tumors in people with NF1 before surgery. It is for patients whose tumors lack a specific protein marker (H3K27me3).
This study monitors people with neurofibromatosis type 1 (NF1) over time to watch for signs that their nerve tumors might turn into cancer. It helps researchers learn which tumors are more likely to change and may lead to better care.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This trial tests two oral targeted drugs, avutometinib and defactinib, for malignant peripheral nerve sheath tumor (MPNST) that has come back or spread. The hope is that these drugs can shrink or slow the tumor where chemotherapy hasn't worked.
Hear when a new MPNST trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.